An object of the present invention is to provide a compound having strong human S1P 2 antagonistic activity in order to develop a useful medicament for therapy of a S1P 2 -mediated disease such as a disease resulting from vascular constriction, fibrosis and respiratory disease. The compound represented by the general formula (I): wherein all the symbols have the same meanings as described in the specification, has a halogen atom or a haloalkyl group and a phenoxy group at certain substitution sites, and thus has strong human S1P 2 antagonistic activity. Therefore, the compound can be a therapeutic agent for a S1P 2 -mediated disease, such as a disease resulting from vascular constriction, fibrosis and respiratory disease.
